

Supporting Material

# Don't overweight weights: Evaluation of weighting strategies for multi-task bioactivity classification models

Lina Humbeck<sup>1\*</sup>, Tobias Morawietz<sup>2</sup>, Noe Sturm<sup>3</sup>, Adam Zalewski<sup>4</sup>, Simon Harnqvist<sup>5§</sup>, Wouter Heyndrickx<sup>6</sup>, Matthew Holmes<sup>5</sup>, Bernd Beck<sup>1</sup>

<sup>1</sup> Medicinal Chemistry Department, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany; lina.humbeck@boehringer-ingelheim.com and bernd.beck@boehringer-ingelheim.com

<sup>2</sup> Bayer AG, Pharmaceuticals, R&D, Digital Technologies, Computational Molecular Design, 42096 Wuppertal, Germany; tobias.morawietz@bayer.com

<sup>3</sup> Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland; noe.sturm@novartis.com

<sup>4</sup> Amgen Research (Munich) GmbH, Staffelseestraße 2, 81477 Munich, Germany; azalewsk@amgen.com

<sup>5</sup> Computational Sciences, GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom; seh589@york.ac.uk and mwh35@bath.ac.uk

<sup>6</sup> Janssen Pharmaceutica N.V., Turnhoutseweg 30, 2340 Beerse, Belgium; wheyndri@its.jnj.com

\* Correspondence: lina.humbeck@boehringer-ingelheim.com





§ Current address: Department of Biology, University of York, YO10 5DD, York UK

**Table S1.** Tested weighting schemes during a pretest for phase II. Bold: selected parameters for testing by multiple partners in phase II.

	fixed	continuous	baseline
<b>thresholds</b>	<b>1000</b> , 2000, 4000, 5000, <b>95% quantile</b>	100, <b>500</b> , <b>1000</b> , 5000, 95% quantile	-
<b>weights</b>	<b>0.6</b> , 0.7, 0.8, <b>0.9</b>	0.01, <b>0.02</b> , 0.04, 0.05, 0.08, 0.1	<b>1</b>


**Table S2.** Phase III results of different weighting schemes averaged over 3 partners and 5 folds for synoptic performance (median and lower quartile task, AUROC) compared to baseline (1) performance. Fractive: fraction of actives, \*statistically significant.

	% better tasks* (averaged over 3 partner)	% worse tasks* (averaged over 3 partner)
Balance down weight	0	2.36
Balance up weight	0	74.08
Based on task size	0	2.24
Fractive down weight	0	0.19
Fractive up weight	0	0.48
Intra down weight balanced	0	1.36
Intra down weigh excess actives	0	1.65
Intra down weight excess inactives	0	2.95
Intra down weight imbalanced	0	5.70
Based on task number	0	5.70




---






**Figure S1.** Phase II results of different weighting schemes averaged over 5 partners and 5 folds for synoptic and deconvoluted performances (median and lower quartile (blue and red boxes), only median (orange and purple boxes) and only lower quartile task (green and brown boxes), AUROC): (a) continuous weighting scheme with weight 0.02 and steps left: 500 and right: 1000, (b) fixed weighting scheme with cutoff 1000 and left: weight of 0.6 and right weight of 0.9, (c) fixed weighting scheme with 95% quantile cutoff and left: weight 0.6 and right weight 0.9, (d) left weighting based on task size, right: weight set to one divided by number of datapoints. Green: better performance than baseline (1), red: worse performance than baseline.



**Figure S2.** Phase II results of different weighting schemes averaged over 5 partners and 5 folds for synoptic and deconvoluted performances (median and lower quartile (blue and red boxes), only median (orange and purple boxes) and only lower quartile task (green and brown boxes), AUPR): (a) continuous weighting scheme with weight 0.02 and steps left: 500 and right: 1000, (b) fixed weighting scheme with cutoff 1000 and left: weight of 0.6 and right weight of 0.9, (c) fixed weighting scheme with 95% quantile cutoff and left: weight 0.6 and right weight 0.9, (d) left weighting based on task size, right: weight set to one divided by number of datapoints. Green: better performance than baseline (1), red: worse performance than baseline.




**Figure S3.** Correlation analysis for one partner of a) AUCPR and b) AUCROC. Results from a second partner are available and comparable and thus not shown. Analyzed factors are: blue: scaled weight, yellow: scaled fraction actives, green: scaled assay size, red: scaled number of scaffolds, purple: scaled scaffold ratio. 00: 1/task\_number, 01: balance down weight, 02: balance up weight, 03: task size (phase III), 04: fractive down weight, 05: fractive up weight, 06: intra down weight balanced, 07: intra down weight excess actives, 08: intra down weight excess inactives, 09: intra down weight imbalanced.



---

**Figure S4.** Phase III results averaged over 5 partners and 5 folds for synoptic and deconvoluted performances (median and lower quartile (blue and red boxes), only median (orange and purple boxes) and only lower quartile task (green and brown boxes), AUROC): (a) global weighting wrt. label balance left: down-weighting balanced tasks and right: down-weight imbalanced tasks, (b) global weighting wrt. fraction actives left: down-weighting excess of actives and right: down-weight excess of inactives, (c) intra assay weighting wrt. label balance left: down-weighting balanced tasks and right: down-weight imbalanced tasks, (d) intra assay weighting wrt. fraction actives left: down-weighting excess of actives and right: down-weight excess of inactives, (e) left: weight set wrt. number of datapoints and right: based on  $1/\text{task\_number}$ . Green: better performance than baseline (1), red: worse performance than baseline.



---

**Figure S5.** Phase III results averaged over 5 partners and 5 folds for synoptic and deconvoluted performances (median and lower quartile (blue and red boxes), only median (orange and purple boxes) and only lower quartile task (green and brown boxes), AUPR): (a) global weighting wrt. label balance left: down-weighting balanced tasks and right: down-weight imbalanced tasks, (b) global weighting wrt. fraction actives left: down-weighting excess of actives and right: down-weight excess of inactives, (c) intra assay weighting wrt. label balance left: down-weighting balanced tasks and right: down-weight imbalanced tasks, (d) intra assay weighting wrt. fraction actives left: down-weighting excess of actives and right: down-weight excess of inactives, (e) left: weight set wrt. number of datapoints and right: based on  $1/\text{task\_number}$ . Green: better performance than baseline (1), red: worse performance than baseline.